Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916493 | 0.90 | SIRT1 (0.52) | SIRT1SIRT2SIRT3TRPM8 | |
| SCHEMBL28766567 | 0.86 | KDM4C (0.46) | SIRT1SIRT2SIRT3KDM4CTAS1R3 | |
| SCHEMBL29673179 | 0.86 | KDM4C (0.46) | SIRT1SIRT2SIRT3KDM4CTAS1R3 | |
| SCHEMBL3353429 | 0.81 | SIRT1 (0.44) | SIRT1SIRT2SIRT3TAS1R3TAS1R1 | |
| SCHEMBL24542973 | 0.81 | LMNA (0.43) | SIRT1SIRT2SIRT3KDM4CTAS1R3 | |
| SCHEMBL29673142 | 0.81 | LMNA (0.43) | SIRT1SIRT2SIRT3KDM4CTAS1R3 | |
| SCHEMBL23088000 | 0.80 | SIRT1 (0.44) | SIRT1SIRT2SIRT3MAPT | |
| SCHEMBL3714922 | 0.78 | MTNR1B (0.52) | ACHE | |
| SCHEMBL15129328 | 0.78 | SIRT1 (0.49) | SIRT1SIRT2SIRT3 | |
| SCHEMBL14916469 | 0.78 | SIRT1 (0.49) | SIRT1SIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289086-A1 | Aminopyrrolidinone Derivatives and Uses Thereof | DUGGAN MARK E (US) | 2013-10-31 | — | — | US | disclosed |
| US-8252829-B2 | Aminopyrrolidinone derivatives and uses thereof | LINK MEDICINE CORPORATION (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2438059-A1 | AMINOPYRROLIDINONE DERIVATIVES AND USES THEREOF | Link Medicine Corporation (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110021590-A1 | AMINOPYRROLIDINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2010141932-A1 | AMINOPYRROLIDINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289086-A1 | Aminopyrrolidinone Derivatives and Uses Thereof | PRMT1, PRMT5, AGTR2 | SIRT1 1158/4885SIRT2 635/4885SIRT3 1446/4885 |
| US-20110021590-A1 | AMINOPYRROLIDINONE DERIVATIVES AND USES THEREOF | PRMT1, PRMT5, AGTR2 | SIRT1 1158/4885SIRT2 635/4885SIRT3 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.